Nothing Special   »   [go: up one dir, main page]

Karmacharya et al., 2023 - Google Patents

Small molecule inhibitors for Unc-51-like autophagy-activating kinase targeting autophagy in cancer

Karmacharya et al., 2023

View HTML
Document ID
13977525963618958879
Author
Karmacharya U
Jung J
Publication year
Publication venue
International journal of molecular sciences

External Links

Snippet

Autophagy is a cellular process that removes damaged components of cells and recycles them as biochemical building blocks. Autophagy can also be induced to protect cells in response to intra-and extracellular stresses, including damage to cellular components …
Continue reading at www.mdpi.com (HTML) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
    • G06Q50/10—Services
    • G06Q50/22—Health care, e.g. hospitals; Social work

Similar Documents

Publication Publication Date Title
Glomb et al. Anti-cancer activity of derivatives of 1, 3, 4-oxadiazole
Wang et al. PARP1 in carcinomas and PARP1 inhibitors as antineoplastic drugs
Perdrix et al. PRIMA-1 and PRIMA-1Met (APR-246): From mutant/wild type p53 reactivation to unexpected mechanisms underlying their potent anti-tumor effect in combinatorial therapies
Ebenezer et al. An overview of the biological evaluation of selected nitrogen-containing heterocycle medicinal chemistry compounds
Czarny et al. Autophagy in DNA damage response
Fallacara et al. A new strategy for glioblastoma treatment: In vitro and in vivo preclinical characterization of Si306, a pyrazolo [3, 4-d] pyrimidine dual Src/P-Glycoprotein inhibitor
Elkaeed et al. New anticancer theobromine derivative targeting egfrwt and egfrt790m: Design, semi-synthesis, in silico, and in vitro anticancer studies
Liu et al. Cucurbitacin B induces the lysosomal degradation of EGFR and suppresses the CIP2A/PP2A/Akt signaling axis in gefitinib-resistant non-small cell lung cancer
Karmacharya et al. Small molecule inhibitors for Unc-51-like autophagy-activating kinase targeting autophagy in cancer
Hamilton Cytotoxic effects of fascaplysin against small cell lung cancer cell lines
Spallarossa et al. The development of FAK inhibitors: a five-year update
Dhuguru et al. Quinazoline based HDAC dual inhibitors as potential anti-cancer agents
Song et al. Repurposing of benzimidazole anthelmintic drugs as cancer therapeutics
Yakkala et al. Prospects of topoisomerase inhibitors as promising anti-cancer agents
Vlachos et al. Repurposing antipsychotics for cancer treatment
Elkaeed et al. Discovery of new VEGFR-2 inhibitors: design, synthesis, anti-proliferative evaluation, docking, and MD simulation studies
Pitucha et al. 2, 4-Dichlorophenoxyacetic Thiosemicarbazides as a new class of compounds against stomach cancer potentially intercalating with DNA
Eissa et al. A new anticancer semisynthetic theobromine derivative targeting EGFR protein: CADDD study
Deveshegowda et al. Development of 1-(4-(Substituted) piperazin-1-yl)-2-((2-((4-methoxybenzyl) thio) pyrimidin-4-yl) oxy) ethanones That Target Poly (ADP-Ribose) Polymerase in Human Breast Cancer Cells
Elkamhawy et al. Scaffold repurposing of in-house small molecule candidates leads to discovery of first-in-class CDK-1/HER-2 dual inhibitors: In vitro and in silico screening
Yang et al. Novel chemicals derived from tadalafil exhibit PRMT5 inhibition and promising activities against breast cancer
Iksen et al. Target identification of 22-(4-Pyridinecarbonyl) jorunnamycin A, a tetrahydroisoquinoline derivative from the sponge Xestospongia sp., in mediating non-small-cell lung cancer cell apoptosis
Al-Wahaibi et al. Design, Synthesis, and Biological Evaluation of Novel 3-Cyanopyridone/Pyrazoline Hybrids as Potential Apoptotic Antiproliferative Agents Targeting EGFR/BRAFV600E Inhibitory Pathways
Abdalla et al. Co-Inhibition of P-gp and Hsp90 by an Isatin-Derived Compound Contributes to the Increase of the Chemosensitivity of MCF7/ADR-Resistant Cells to Doxorubicin
Kauerová et al. Salicylanilides and their anticancer properties